 Debashis Ghosh
Concepts (696)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Data Interpretation, Statistical | 27 | 2020 | 327 | 5.180 |
Why?
| | Models, Statistical | 42 | 2021 | 614 | 4.560 |
Why?
| | Gene Expression Profiling | 51 | 2021 | 1461 | 4.510 |
Why?
| | Algorithms | 36 | 2023 | 1464 | 4.110 |
Why?
| | Oligonucleotide Array Sequence Analysis | 35 | 2016 | 682 | 3.550 |
Why?
| | Biomarkers, Tumor | 24 | 2022 | 982 | 2.730 |
Why?
| | Metabolomics | 9 | 2022 | 521 | 2.660 |
Why?
| | Machine Learning | 8 | 2022 | 322 | 2.540 |
Why?
| | Biometry | 13 | 2011 | 62 | 2.480 |
Why?
| | Computer Simulation | 31 | 2022 | 871 | 2.200 |
Why?
| | Neoplasms | 24 | 2022 | 2054 | 2.130 |
Why?
| | Regression Analysis | 13 | 2021 | 959 | 1.680 |
Why?
| | Genomics | 11 | 2017 | 618 | 1.590 |
Why?
| | Neoplasm Proteins | 12 | 2018 | 382 | 1.540 |
Why?
| | Models, Biological | 14 | 2021 | 1573 | 1.510 |
Why?
| | Computational Biology | 17 | 2021 | 605 | 1.510 |
Why?
| | Prostatic Neoplasms | 25 | 2012 | 1000 | 1.500 |
Why?
| | Biomarkers | 14 | 2021 | 3346 | 1.440 |
Why?
| | Causality | 4 | 2022 | 113 | 1.340 |
Why?
| | Statistics, Nonparametric | 8 | 2019 | 412 | 1.320 |
Why?
| | Gene Expression Regulation, Neoplastic | 22 | 2021 | 1113 | 1.310 |
Why?
| | Proportional Hazards Models | 10 | 2022 | 1095 | 1.300 |
Why?
| | Biostatistics | 3 | 2014 | 16 | 1.250 |
Why?
| | Software | 13 | 2022 | 577 | 1.240 |
Why?
| | Humans | 158 | 2023 | 109930 | 1.110 |
Why?
| | Meta-Analysis as Topic | 4 | 2014 | 159 | 1.080 |
Why?
| | Colonic Neoplasms | 2 | 2022 | 189 | 1.020 |
Why?
| | Magnetoencephalography | 2 | 2021 | 118 | 1.020 |
Why?
| | Survival Analysis | 11 | 2017 | 1207 | 0.970 |
Why?
| | Lung Neoplasms | 6 | 2022 | 2165 | 0.940 |
Why?
| | Genetic Association Studies | 5 | 2019 | 349 | 0.920 |
Why?
| | Cognitive Dysfunction | 4 | 2021 | 325 | 0.910 |
Why?
| | Multivariate Analysis | 16 | 2022 | 1459 | 0.900 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 3 | 2023 | 1314 | 0.880 |
Why?
| | Mass Spectrometry | 6 | 2022 | 563 | 0.870 |
Why?
| | Connectome | 2 | 2021 | 68 | 0.860 |
Why?
| | Parkinsonian Disorders | 1 | 2021 | 28 | 0.840 |
Why?
| | Microscopy | 2 | 2021 | 114 | 0.820 |
Why?
| | Propensity Score | 4 | 2018 | 238 | 0.810 |
Why?
| | Endpoint Determination | 2 | 2011 | 62 | 0.800 |
Why?
| | Brain Mapping | 2 | 2021 | 598 | 0.770 |
Why?
| | High-Throughput Screening Assays | 2 | 2012 | 101 | 0.760 |
Why?
| | Clinical Trials as Topic | 4 | 2022 | 953 | 0.760 |
Why?
| | Models, Genetic | 10 | 2019 | 525 | 0.750 |
Why?
| | Diagnostic Imaging | 1 | 2022 | 267 | 0.740 |
Why?
| | Risk Assessment | 8 | 2020 | 2979 | 0.740 |
Why?
| | Radiographic Image Interpretation, Computer-Assisted | 1 | 2020 | 105 | 0.720 |
Why?
| | Genetic Variation | 4 | 2019 | 881 | 0.710 |
Why?
| | Glioma | 1 | 2022 | 289 | 0.700 |
Why?
| | DNA Copy Number Variations | 2 | 2017 | 158 | 0.700 |
Why?
| | Quantitative Trait, Heritable | 2 | 2018 | 112 | 0.700 |
Why?
| | Cardiovascular Diseases | 5 | 2022 | 1658 | 0.690 |
Why?
| | Databases, Factual | 11 | 2020 | 1156 | 0.680 |
Why?
| | Metabolome | 1 | 2021 | 297 | 0.680 |
Why?
| | Randomized Controlled Trials as Topic | 5 | 2021 | 1174 | 0.670 |
Why?
| | Logistic Models | 12 | 2020 | 1847 | 0.650 |
Why?
| | Databases, Genetic | 10 | 2021 | 261 | 0.650 |
Why?
| | Phenotype | 10 | 2021 | 2770 | 0.640 |
Why?
| | Epidemiologic Methods | 2 | 2007 | 66 | 0.630 |
Why?
| | Reproducibility of Results | 16 | 2021 | 2724 | 0.620 |
Why?
| | Immunohistochemistry | 11 | 2022 | 1601 | 0.600 |
Why?
| | Retinol-Binding Proteins | 2 | 2014 | 11 | 0.600 |
Why?
| | Eye Proteins | 3 | 2014 | 64 | 0.590 |
Why?
| | Autism Spectrum Disorder | 2 | 2017 | 260 | 0.570 |
Why?
| | Markov Chains | 7 | 2017 | 117 | 0.570 |
Why?
| | Linear Models | 7 | 2018 | 833 | 0.540 |
Why?
| | Empirical Research | 2 | 2012 | 26 | 0.530 |
Why?
| | Diagnosis, Computer-Assisted | 4 | 2008 | 68 | 0.530 |
Why?
| | Carcinoma, Squamous Cell | 4 | 2017 | 579 | 0.500 |
Why?
| | Protein Tyrosine Phosphatases | 3 | 2019 | 101 | 0.490 |
Why?
| | Bayes Theorem | 6 | 2012 | 327 | 0.490 |
Why?
| | Genome-Wide Association Study | 7 | 2018 | 1185 | 0.480 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2022 | 1002 | 0.480 |
Why?
| | Disease Progression | 14 | 2021 | 2219 | 0.470 |
Why?
| | Bias | 5 | 2022 | 187 | 0.460 |
Why?
| | Diabetes Mellitus, Type 2 | 3 | 2022 | 1824 | 0.460 |
Why?
| | Cluster Analysis | 9 | 2023 | 488 | 0.450 |
Why?
| | Treatment Outcome | 7 | 2021 | 9037 | 0.450 |
Why?
| | Tissue Array Analysis | 3 | 2008 | 51 | 0.450 |
Why?
| | Oncogenes | 1 | 2013 | 118 | 0.440 |
Why?
| | Aromatase | 1 | 2012 | 29 | 0.440 |
Why?
| | Liver Neoplasms | 1 | 2015 | 355 | 0.430 |
Why?
| | Sulfhydryl Compounds | 1 | 2014 | 175 | 0.430 |
Why?
| | Genome | 5 | 2017 | 233 | 0.420 |
Why?
| | Adenocarcinoma | 4 | 2017 | 658 | 0.420 |
Why?
| | Cytochrome P-450 Enzyme System | 1 | 2012 | 111 | 0.420 |
Why?
| | Male | 59 | 2021 | 55761 | 0.420 |
Why?
| | Alzheimer Disease | 3 | 2015 | 514 | 0.410 |
Why?
| | Cardiac Catheterization | 1 | 2015 | 523 | 0.400 |
Why?
| | Supervised Machine Learning | 2 | 2021 | 12 | 0.390 |
Why?
| | Polymorphism, Single Nucleotide | 5 | 2019 | 1857 | 0.390 |
Why?
| | Endoplasmic Reticulum | 1 | 2012 | 200 | 0.380 |
Why?
| | Proteomics | 5 | 2009 | 758 | 0.380 |
Why?
| | Antioxidants | 1 | 2014 | 553 | 0.370 |
Why?
| | Brain | 3 | 2019 | 2565 | 0.370 |
Why?
| | Gene Expression | 3 | 2014 | 1374 | 0.370 |
Why?
| | Stem Cells | 3 | 2020 | 473 | 0.370 |
Why?
| | Ki-67 Antigen | 2 | 2020 | 104 | 0.360 |
Why?
| | Nerve Tissue Proteins | 3 | 2020 | 510 | 0.360 |
Why?
| | Epidemiologic Research Design | 1 | 2009 | 31 | 0.360 |
Why?
| | Tumor Microenvironment | 2 | 2022 | 387 | 0.360 |
Why?
| | Signal Transduction | 9 | 2023 | 4138 | 0.360 |
Why?
| | Gene Dosage | 1 | 2010 | 136 | 0.360 |
Why?
| | Chromatin Immunoprecipitation | 3 | 2017 | 111 | 0.350 |
Why?
| | Carcinoma | 2 | 2007 | 194 | 0.340 |
Why?
| | Emigration and Immigration | 1 | 2008 | 38 | 0.340 |
Why?
| | Bone Marrow Transplantation | 2 | 2008 | 259 | 0.340 |
Why?
| | Sensitivity and Specificity | 10 | 2015 | 1667 | 0.340 |
Why?
| | Protein Array Analysis | 8 | 2009 | 48 | 0.340 |
Why?
| | Image Processing, Computer-Assisted | 4 | 2021 | 673 | 0.340 |
Why?
| | Racemases and Epimerases | 5 | 2006 | 10 | 0.340 |
Why?
| | DNA-Binding Proteins | 7 | 2018 | 1168 | 0.340 |
Why?
| | Statistical Distributions | 1 | 2008 | 8 | 0.330 |
Why?
| | Probability | 3 | 2021 | 301 | 0.330 |
Why?
| | Flow Cytometry | 2 | 2022 | 849 | 0.330 |
Why?
| | Chromosome Mapping | 6 | 2017 | 454 | 0.330 |
Why?
| | Proteome | 3 | 2007 | 310 | 0.330 |
Why?
| | Research Design | 5 | 2021 | 936 | 0.320 |
Why?
| | Pancreas | 2 | 2020 | 165 | 0.320 |
Why?
| | Arrhythmias, Cardiac | 2 | 2020 | 319 | 0.310 |
Why?
| | Tumor Burden | 1 | 2008 | 246 | 0.310 |
Why?
| | Diabetes Mellitus | 5 | 2022 | 815 | 0.310 |
Why?
| | Aged | 27 | 2022 | 19315 | 0.300 |
Why?
| | Urinary Bladder Neoplasms | 2 | 2021 | 191 | 0.300 |
Why?
| | Female | 42 | 2022 | 58326 | 0.290 |
Why?
| | Triple Negative Breast Neoplasms | 2 | 2019 | 151 | 0.290 |
Why?
| | Placenta | 1 | 2012 | 613 | 0.290 |
Why?
| | Neoplasm Staging | 6 | 2019 | 1096 | 0.280 |
Why?
| | Monte Carlo Method | 4 | 2017 | 136 | 0.280 |
Why?
| | Nerve Net | 2 | 2019 | 264 | 0.280 |
Why?
| | Magnetic Resonance Imaging | 5 | 2022 | 2968 | 0.280 |
Why?
| | Cell Proliferation | 5 | 2021 | 2158 | 0.280 |
Why?
| | Homeodomain Proteins | 4 | 2020 | 409 | 0.280 |
Why?
| | Cell Nucleus | 2 | 2019 | 510 | 0.270 |
Why?
| | Middle Aged | 29 | 2022 | 26870 | 0.270 |
Why?
| | False Positive Reactions | 4 | 2012 | 107 | 0.270 |
Why?
| | Replication Origin | 1 | 2004 | 12 | 0.260 |
Why?
| | Neoplasm Recurrence, Local | 3 | 2019 | 780 | 0.260 |
Why?
| | Crystallography, X-Ray | 3 | 2019 | 317 | 0.260 |
Why?
| | Histones | 4 | 2020 | 487 | 0.250 |
Why?
| | Carrier Proteins | 2 | 2007 | 635 | 0.250 |
Why?
| | Leukemia | 1 | 2006 | 206 | 0.250 |
Why?
| | ROC Curve | 5 | 2020 | 455 | 0.250 |
Why?
| | Coculture Techniques | 1 | 2004 | 167 | 0.240 |
Why?
| | Risk Factors | 12 | 2022 | 8496 | 0.240 |
Why?
| | Autoantibodies | 5 | 2020 | 742 | 0.240 |
Why?
| | Membrane Transport Proteins | 1 | 2004 | 118 | 0.240 |
Why?
| | Breast Neoplasms | 7 | 2014 | 1778 | 0.240 |
Why?
| | Sample Size | 3 | 2008 | 123 | 0.240 |
Why?
| | Statistics as Topic | 2 | 2005 | 305 | 0.240 |
Why?
| | Carcinogens | 1 | 2003 | 94 | 0.230 |
Why?
| | Common Variable Immunodeficiency | 1 | 2023 | 26 | 0.230 |
Why?
| | Neoplasms, Experimental | 1 | 2003 | 134 | 0.230 |
Why?
| | Personality | 1 | 2004 | 118 | 0.230 |
Why?
| | Neuroimaging | 2 | 2015 | 226 | 0.230 |
Why?
| | Pancreatic Neoplasms | 3 | 2019 | 347 | 0.220 |
Why?
| | Lymphoma, Large B-Cell, Diffuse | 2 | 2019 | 92 | 0.220 |
Why?
| | Promoter Regions, Genetic | 3 | 2009 | 986 | 0.220 |
Why?
| | Membrane Glycoproteins | 1 | 2004 | 359 | 0.220 |
Why?
| | Emphysema | 1 | 2023 | 125 | 0.220 |
Why?
| | Artificial Intelligence | 3 | 2008 | 129 | 0.220 |
Why?
| | Head and Neck Neoplasms | 2 | 2017 | 407 | 0.210 |
Why?
| | Epilepsies, Partial | 1 | 2021 | 34 | 0.210 |
Why?
| | Brain Waves | 1 | 2021 | 30 | 0.210 |
Why?
| | Epilepsy | 2 | 2021 | 273 | 0.210 |
Why?
| | Receptors, Androgen | 2 | 2021 | 125 | 0.200 |
Why?
| | Drug Resistant Epilepsy | 1 | 2021 | 43 | 0.200 |
Why?
| | Anxiety Disorders | 1 | 2004 | 310 | 0.200 |
Why?
| | Adult | 19 | 2022 | 30014 | 0.200 |
Why?
| | Genotype | 8 | 2019 | 1673 | 0.200 |
Why?
| | Hyaluronan Receptors | 1 | 2021 | 76 | 0.200 |
Why?
| | Polymorphism, Genetic | 1 | 2004 | 577 | 0.200 |
Why?
| | Lymphocytes | 2 | 2023 | 307 | 0.200 |
Why?
| | Toll-Like Receptors | 1 | 2020 | 122 | 0.190 |
Why?
| | Tandem Mass Spectrometry | 3 | 2014 | 376 | 0.190 |
Why?
| | Pattern Recognition, Automated | 4 | 2009 | 82 | 0.190 |
Why?
| | Case-Control Studies | 7 | 2020 | 2996 | 0.190 |
Why?
| | Recurrence | 4 | 2010 | 977 | 0.190 |
Why?
| | Mexican Americans | 3 | 2008 | 87 | 0.190 |
Why?
| | Pulmonary Emphysema | 1 | 2023 | 347 | 0.190 |
Why?
| | Exome | 2 | 2018 | 203 | 0.190 |
Why?
| | Prognosis | 11 | 2021 | 3252 | 0.190 |
Why?
| | Tretinoin | 1 | 2020 | 93 | 0.190 |
Why?
| | Herpes Zoster Vaccine | 1 | 2022 | 157 | 0.190 |
Why?
| | Hypoglycemic Agents | 2 | 2021 | 620 | 0.180 |
Why?
| | Radiography | 1 | 2022 | 843 | 0.180 |
Why?
| | Gene Expression Regulation | 4 | 2014 | 2125 | 0.180 |
Why?
| | Disease | 1 | 2019 | 88 | 0.180 |
Why?
| | Core Binding Factor Alpha 1 Subunit | 1 | 2019 | 51 | 0.180 |
Why?
| | Bone Regeneration | 1 | 2019 | 29 | 0.180 |
Why?
| | Small Molecule Libraries | 1 | 2019 | 67 | 0.170 |
Why?
| | Functional Neuroimaging | 1 | 2019 | 71 | 0.170 |
Why?
| | Precancerous Conditions | 1 | 2020 | 141 | 0.170 |
Why?
| | Neoplasms, Second Primary | 1 | 2019 | 82 | 0.170 |
Why?
| | Environmental Exposure | 2 | 2017 | 393 | 0.170 |
Why?
| | SOXB1 Transcription Factors | 1 | 2019 | 58 | 0.170 |
Why?
| | Wilms Tumor | 1 | 2019 | 72 | 0.170 |
Why?
| | Pituitary Gland | 2 | 2009 | 153 | 0.170 |
Why?
| | Lung Diseases, Interstitial | 1 | 2023 | 414 | 0.170 |
Why?
| | Transcription, Genetic | 7 | 2013 | 1018 | 0.170 |
Why?
| | Monocytes | 1 | 2020 | 424 | 0.170 |
Why?
| | Observational Studies as Topic | 1 | 2018 | 83 | 0.170 |
Why?
| | Protein Phosphatase 2 | 1 | 2018 | 33 | 0.170 |
Why?
| | Genetic Markers | 3 | 2015 | 344 | 0.170 |
Why?
| | Herpes Zoster | 1 | 2022 | 324 | 0.160 |
Why?
| | Peptides | 3 | 2007 | 634 | 0.160 |
Why?
| | Blood Glucose | 2 | 2022 | 1317 | 0.160 |
Why?
| | Insulin-Secreting Cells | 1 | 2020 | 176 | 0.160 |
Why?
| | Parkinson Disease | 1 | 2021 | 319 | 0.160 |
Why?
| | RNA, Neoplasm | 1 | 2017 | 69 | 0.160 |
Why?
| | CD24 Antigen | 1 | 2017 | 16 | 0.160 |
Why?
| | Genes, Neoplasm | 3 | 2007 | 19 | 0.160 |
Why?
| | DNA Methylation | 3 | 2017 | 441 | 0.160 |
Why?
| | Animals | 18 | 2021 | 29541 | 0.160 |
Why?
| | DNA, Neoplasm | 1 | 2017 | 144 | 0.160 |
Why?
| | Clinical Laboratory Techniques | 1 | 2018 | 83 | 0.160 |
Why?
| | Child Health | 1 | 2019 | 117 | 0.160 |
Why?
| | Host-Pathogen Interactions | 1 | 2019 | 213 | 0.160 |
Why?
| | Neoplasm Metastasis | 6 | 2019 | 561 | 0.160 |
Why?
| | Clinical Trials, Phase III as Topic | 3 | 2012 | 79 | 0.160 |
Why?
| | Proto-Oncogene Proteins c-myc | 1 | 2018 | 115 | 0.160 |
Why?
| | Lymph Nodes | 1 | 2019 | 310 | 0.160 |
Why?
| | Epigenomics | 1 | 2017 | 99 | 0.160 |
Why?
| | RNA, Messenger | 6 | 2017 | 2427 | 0.150 |
Why?
| | Transcription Factors | 6 | 2017 | 1315 | 0.150 |
Why?
| | Mice | 14 | 2021 | 12581 | 0.150 |
Why?
| | Induction Chemotherapy | 1 | 2017 | 54 | 0.150 |
Why?
| | Image Interpretation, Computer-Assisted | 1 | 2019 | 217 | 0.150 |
Why?
| | B7-H1 Antigen | 1 | 2018 | 121 | 0.150 |
Why?
| | Chromosome Aberrations | 2 | 2007 | 125 | 0.150 |
Why?
| | Beryllium | 1 | 2018 | 139 | 0.150 |
Why?
| | Principal Component Analysis | 1 | 2017 | 172 | 0.150 |
Why?
| | Protein Binding | 4 | 2019 | 1559 | 0.150 |
Why?
| | Chemoradiotherapy, Adjuvant | 1 | 2016 | 33 | 0.150 |
Why?
| | Models, Neurological | 1 | 2019 | 260 | 0.150 |
Why?
| | Anesthesia Department, Hospital | 1 | 2016 | 1 | 0.150 |
Why?
| | RNA, Small Interfering | 1 | 2019 | 528 | 0.150 |
Why?
| | Up-Regulation | 2 | 2018 | 792 | 0.150 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2019 | 385 | 0.150 |
Why?
| | Nurse Anesthetists | 1 | 2016 | 3 | 0.150 |
Why?
| | Osteogenesis | 1 | 2019 | 214 | 0.150 |
Why?
| | Normal Distribution | 2 | 2014 | 22 | 0.150 |
Why?
| | Analysis of Variance | 3 | 2017 | 1341 | 0.150 |
Why?
| | Salivary Gland Neoplasms | 1 | 2016 | 31 | 0.150 |
Why?
| | DNA, Complementary | 3 | 2005 | 234 | 0.150 |
Why?
| | Anesthesia, Obstetrical | 1 | 2016 | 10 | 0.150 |
Why?
| | Anus Neoplasms | 1 | 2016 | 22 | 0.150 |
Why?
| | Anesthesiologists | 1 | 2016 | 15 | 0.150 |
Why?
| | Aged, 80 and over | 13 | 2022 | 6499 | 0.150 |
Why?
| | Analgesia, Obstetrical | 1 | 2016 | 15 | 0.150 |
Why?
| | Tachycardia, Ventricular | 1 | 2018 | 176 | 0.150 |
Why?
| | Heart Arrest | 1 | 2020 | 289 | 0.150 |
Why?
| | Transcriptional Activation | 1 | 2018 | 306 | 0.150 |
Why?
| | Memory, Short-Term | 1 | 2019 | 265 | 0.150 |
Why?
| | Cough | 2 | 2007 | 104 | 0.140 |
Why?
| | Health Services Research | 1 | 2019 | 356 | 0.140 |
Why?
| | Air Pollution | 2 | 2017 | 187 | 0.140 |
Why?
| | Berylliosis | 1 | 2018 | 168 | 0.140 |
Why?
| | ErbB Receptors | 2 | 2012 | 564 | 0.140 |
Why?
| | Cell Differentiation | 2 | 2020 | 1326 | 0.140 |
Why?
| | Respiratory Sounds | 2 | 2007 | 112 | 0.140 |
Why?
| | Gastrointestinal Microbiome | 1 | 2022 | 495 | 0.140 |
Why?
| | Kaplan-Meier Estimate | 3 | 2017 | 849 | 0.140 |
Why?
| | Anal Canal | 1 | 2016 | 80 | 0.140 |
Why?
| | Colorectal Neoplasms | 3 | 2012 | 563 | 0.140 |
Why?
| | Cell Transformation, Neoplastic | 4 | 2007 | 273 | 0.140 |
Why?
| | HIV Infections | 3 | 2022 | 2360 | 0.140 |
Why?
| | Models, Theoretical | 1 | 2020 | 546 | 0.140 |
Why?
| | Cancer Survivors | 1 | 2019 | 196 | 0.140 |
Why?
| | Tumor Cells, Cultured | 4 | 2021 | 825 | 0.140 |
Why?
| | Neoplastic Stem Cells | 1 | 2019 | 324 | 0.130 |
Why?
| | Kidney Neoplasms | 1 | 2019 | 331 | 0.130 |
Why?
| | Atrial Fibrillation | 1 | 2020 | 389 | 0.130 |
Why?
| | Nuclear Proteins | 1 | 2019 | 535 | 0.130 |
Why?
| | Hypocreales | 1 | 2014 | 8 | 0.130 |
Why?
| | Leishmaniasis, Visceral | 1 | 2014 | 5 | 0.130 |
Why?
| | Cell Line, Tumor | 7 | 2019 | 2672 | 0.130 |
Why?
| | Influenza Vaccines | 1 | 2019 | 447 | 0.130 |
Why?
| | Risk | 1 | 2017 | 838 | 0.130 |
Why?
| | Executive Function | 1 | 2019 | 401 | 0.130 |
Why?
| | Discriminant Analysis | 3 | 2020 | 37 | 0.130 |
Why?
| | Longitudinal Studies | 4 | 2018 | 2457 | 0.130 |
Why?
| | Survival Rate | 4 | 2019 | 1652 | 0.130 |
Why?
| | Ants | 1 | 2014 | 28 | 0.130 |
Why?
| | Metmyoglobin | 1 | 2014 | 1 | 0.130 |
Why?
| | Time Factors | 5 | 2016 | 6362 | 0.130 |
Why?
| | Sulfonic Acids | 1 | 2014 | 10 | 0.130 |
Why?
| | Genetic Predisposition to Disease | 4 | 2019 | 2056 | 0.130 |
Why?
| | Chromatography, Ion Exchange | 1 | 2014 | 43 | 0.130 |
Why?
| | Influenza, Human | 1 | 2019 | 469 | 0.130 |
Why?
| | Trans-Activators | 3 | 2020 | 270 | 0.130 |
Why?
| | Treatment Failure | 1 | 2015 | 331 | 0.130 |
Why?
| | Chromatography, Affinity | 1 | 2014 | 83 | 0.130 |
Why?
| | Benzothiazoles | 1 | 2014 | 35 | 0.120 |
Why?
| | Chromatography, Gel | 1 | 2014 | 111 | 0.120 |
Why?
| | Defibrillators, Implantable | 1 | 2018 | 405 | 0.120 |
Why?
| | Acquired Immunodeficiency Syndrome | 1 | 2015 | 208 | 0.120 |
Why?
| | Free Radical Scavengers | 1 | 2014 | 85 | 0.120 |
Why?
| | Embryonic Stem Cells | 1 | 2014 | 90 | 0.120 |
Why?
| | Crystallization | 1 | 2014 | 118 | 0.120 |
Why?
| | Cohort Studies | 8 | 2017 | 4832 | 0.120 |
Why?
| | Electronic Health Records | 1 | 2020 | 707 | 0.120 |
Why?
| | Odds Ratio | 3 | 2020 | 954 | 0.120 |
Why?
| | Brain Diseases | 1 | 2015 | 136 | 0.120 |
Why?
| | Spectrometry, Fluorescence | 1 | 2014 | 153 | 0.120 |
Why?
| | Schizophrenia | 1 | 2019 | 593 | 0.120 |
Why?
| | Estradiol | 2 | 2014 | 462 | 0.120 |
Why?
| | Protein Structure, Tertiary | 2 | 2012 | 652 | 0.110 |
Why?
| | Arthritis, Rheumatoid | 1 | 2020 | 924 | 0.110 |
Why?
| | Xenograft Model Antitumor Assays | 3 | 2021 | 731 | 0.110 |
Why?
| | RNA, Viral | 1 | 2015 | 455 | 0.110 |
Why?
| | Influenza A Virus, H5N1 Subtype | 1 | 2011 | 3 | 0.110 |
Why?
| | Heme | 1 | 2012 | 39 | 0.110 |
Why?
| | Least-Squares Analysis | 2 | 2020 | 70 | 0.110 |
Why?
| | Transcription Factor Pit-1 | 1 | 2011 | 23 | 0.110 |
Why?
| | Otx Transcription Factors | 1 | 2011 | 12 | 0.110 |
Why?
| | Hypopituitarism | 1 | 2011 | 15 | 0.110 |
Why?
| | Motion | 1 | 2012 | 82 | 0.110 |
Why?
| | Catalytic Domain | 1 | 2012 | 156 | 0.110 |
Why?
| | Brucella suis | 1 | 2011 | 1 | 0.110 |
Why?
| | Regulatory Sequences, Nucleic Acid | 2 | 2017 | 66 | 0.100 |
Why?
| | Brucellosis | 1 | 2011 | 4 | 0.100 |
Why?
| | Gene Expression Regulation, Viral | 1 | 2011 | 70 | 0.100 |
Why?
| | Pediatrics | 1 | 2019 | 884 | 0.100 |
Why?
| | Retina | 1 | 2014 | 262 | 0.100 |
Why?
| | Caspase 2 | 1 | 2011 | 14 | 0.100 |
Why?
| | Lung | 2 | 2023 | 3398 | 0.100 |
Why?
| | Prostatic Intraepithelial Neoplasia | 2 | 2008 | 13 | 0.100 |
Why?
| | Chemoradiotherapy | 3 | 2017 | 180 | 0.100 |
Why?
| | Stress Disorders, Post-Traumatic | 2 | 2019 | 695 | 0.100 |
Why?
| | MicroRNAs | 1 | 2017 | 585 | 0.100 |
Why?
| | Cattle | 1 | 2014 | 886 | 0.100 |
Why?
| | Catalysis | 1 | 2012 | 264 | 0.100 |
Why?
| | Lipid Bilayers | 1 | 2012 | 82 | 0.100 |
Why?
| | Neoplasm Invasiveness | 4 | 2017 | 399 | 0.100 |
Why?
| | Pharmacogenetics | 1 | 2012 | 144 | 0.100 |
Why?
| | Vaccination | 1 | 2019 | 1099 | 0.100 |
Why?
| | Age Factors | 3 | 2020 | 2935 | 0.100 |
Why?
| | Chemokines | 1 | 2011 | 189 | 0.100 |
Why?
| | Mental Disorders | 1 | 2019 | 909 | 0.100 |
Why?
| | Oxidation-Reduction | 1 | 2014 | 883 | 0.100 |
Why?
| | Tomography, X-Ray Computed | 1 | 2020 | 2264 | 0.100 |
Why?
| | Influenza A Virus, H1N1 Subtype | 1 | 2011 | 122 | 0.100 |
Why?
| | Child | 8 | 2021 | 16704 | 0.100 |
Why?
| | Prevalence | 2 | 2015 | 2202 | 0.100 |
Why?
| | Zalcitabine | 1 | 2010 | 2 | 0.100 |
Why?
| | Gene Silencing | 2 | 2007 | 159 | 0.100 |
Why?
| | Didanosine | 1 | 2010 | 15 | 0.100 |
Why?
| | Activities of Daily Living | 2 | 2003 | 362 | 0.100 |
Why?
| | Nonlinear Dynamics | 1 | 2010 | 92 | 0.100 |
Why?
| | Antibody Formation | 2 | 2007 | 180 | 0.100 |
Why?
| | Pregnancy | 4 | 2017 | 5270 | 0.090 |
Why?
| | Phosphoglycerate Kinase | 1 | 2009 | 2 | 0.090 |
Why?
| | Protein Conformation | 1 | 2012 | 626 | 0.090 |
Why?
| | Sarcosine | 1 | 2009 | 9 | 0.090 |
Why?
| | Decision Trees | 2 | 2020 | 91 | 0.090 |
Why?
| | AIDS-Related Opportunistic Infections | 1 | 2010 | 106 | 0.090 |
Why?
| | Delivery of Health Care | 1 | 2016 | 775 | 0.090 |
Why?
| | Retinitis Pigmentosa | 1 | 2008 | 17 | 0.090 |
Why?
| | Peptide Library | 2 | 2007 | 44 | 0.090 |
Why?
| | Androgens | 2 | 2009 | 160 | 0.090 |
Why?
| | Genes, Recessive | 1 | 2008 | 71 | 0.090 |
Why?
| | Anti-HIV Agents | 1 | 2015 | 645 | 0.090 |
Why?
| | Follow-Up Studies | 4 | 2019 | 4471 | 0.090 |
Why?
| | Psoriasis | 1 | 2009 | 78 | 0.090 |
Why?
| | Respiratory Tract Infections | 1 | 2011 | 274 | 0.080 |
Why?
| | Homozygote | 1 | 2008 | 167 | 0.080 |
Why?
| | Acculturation | 1 | 2008 | 50 | 0.080 |
Why?
| | CD8-Positive T-Lymphocytes | 2 | 2023 | 360 | 0.080 |
Why?
| | Complex Mixtures | 1 | 2007 | 14 | 0.080 |
Why?
| | Blindness | 1 | 2008 | 29 | 0.080 |
Why?
| | Proteins | 2 | 2003 | 829 | 0.080 |
Why?
| | Pituitary Neoplasms | 1 | 2009 | 153 | 0.080 |
Why?
| | Uncertainty | 1 | 2008 | 99 | 0.080 |
Why?
| | Receptors, Adrenergic, beta-2 | 1 | 2007 | 43 | 0.080 |
Why?
| | Practice Patterns, Physicians' | 1 | 2016 | 1149 | 0.080 |
Why?
| | Lymphatic Metastasis | 2 | 2019 | 226 | 0.080 |
Why?
| | Glaucoma | 1 | 2010 | 206 | 0.080 |
Why?
| | Mice, Nude | 2 | 2021 | 617 | 0.080 |
Why?
| | Confidence Intervals | 1 | 2008 | 321 | 0.080 |
Why?
| | Leisure Activities | 1 | 2007 | 28 | 0.080 |
Why?
| | Exercise | 1 | 2018 | 1748 | 0.080 |
Why?
| | Socioeconomic Factors | 2 | 2008 | 1079 | 0.080 |
Why?
| | Antibodies, Neoplasm | 1 | 2007 | 27 | 0.080 |
Why?
| | Genes, myc | 1 | 2007 | 45 | 0.080 |
Why?
| | Young Adult | 6 | 2020 | 10164 | 0.080 |
Why?
| | Genome, Human | 4 | 2016 | 338 | 0.080 |
Why?
| | Self Concept | 1 | 2009 | 206 | 0.080 |
Why?
| | Genome, Bacterial | 2 | 2006 | 93 | 0.080 |
Why?
| | Decision Theory | 1 | 2006 | 1 | 0.080 |
Why?
| | Nails | 1 | 2007 | 10 | 0.080 |
Why?
| | Mutation, Missense | 1 | 2008 | 274 | 0.080 |
Why?
| | Arsenic | 1 | 2007 | 32 | 0.080 |
Why?
| | DNA, Bacterial | 2 | 2006 | 245 | 0.070 |
Why?
| | Genes, MHC Class II | 1 | 2006 | 26 | 0.070 |
Why?
| | Haemophilus influenzae | 1 | 2006 | 55 | 0.070 |
Why?
| | Serine Endopeptidases | 1 | 2007 | 90 | 0.070 |
Why?
| | Haemophilus Infections | 1 | 2006 | 36 | 0.070 |
Why?
| | Pharynx | 1 | 2006 | 49 | 0.070 |
Why?
| | United States | 7 | 2018 | 12165 | 0.070 |
Why?
| | Information Storage and Retrieval | 1 | 2007 | 142 | 0.070 |
Why?
| | Diabetic Retinopathy | 1 | 2008 | 117 | 0.070 |
Why?
| | Cell Cycle Proteins | 2 | 2007 | 502 | 0.070 |
Why?
| | Death Certificates | 1 | 2006 | 25 | 0.070 |
Why?
| | Calibration | 2 | 2022 | 110 | 0.070 |
Why?
| | Histocompatibility Antigens Class II | 1 | 2006 | 138 | 0.070 |
Why?
| | GATA3 Transcription Factor | 1 | 2005 | 27 | 0.070 |
Why?
| | Quantitative Trait Loci | 1 | 2008 | 308 | 0.070 |
Why?
| | Apoptosis | 3 | 2021 | 2316 | 0.070 |
Why?
| | Lipids | 1 | 2009 | 552 | 0.070 |
Why?
| | Environmental Pollutants | 1 | 2007 | 96 | 0.070 |
Why?
| | Chromosomes, Human, Pair 17 | 1 | 2005 | 58 | 0.070 |
Why?
| | Estrogens | 1 | 2008 | 305 | 0.070 |
Why?
| | Carcinoma, Intraductal, Noninfiltrating | 1 | 2005 | 43 | 0.070 |
Why?
| | Protein Interaction Mapping | 1 | 2005 | 89 | 0.070 |
Why?
| | Macrophages | 1 | 2011 | 1037 | 0.070 |
Why?
| | Repressor Proteins | 1 | 2007 | 303 | 0.070 |
Why?
| | Disease-Free Survival | 3 | 2017 | 632 | 0.070 |
Why?
| | Body Mass Index | 2 | 2016 | 1985 | 0.070 |
Why?
| | Area Under Curve | 2 | 2020 | 279 | 0.070 |
Why?
| | Retinal Rod Photoreceptor Cells | 1 | 2004 | 12 | 0.070 |
Why?
| | Environmental Monitoring | 1 | 2007 | 275 | 0.070 |
Why?
| | Retinal Cone Photoreceptor Cells | 1 | 2004 | 15 | 0.060 |
Why?
| | Poisson Distribution | 1 | 2004 | 70 | 0.060 |
Why?
| | Linkage Disequilibrium | 1 | 2005 | 249 | 0.060 |
Why?
| | Sputum | 1 | 2006 | 277 | 0.060 |
Why?
| | Culture Techniques | 1 | 2004 | 74 | 0.060 |
Why?
| | Granulomatous Disease, Chronic | 1 | 2004 | 51 | 0.060 |
Why?
| | Bacterial Typing Techniques | 1 | 2004 | 29 | 0.060 |
Why?
| | Fluorescent Antibody Technique | 2 | 2020 | 348 | 0.060 |
Why?
| | Otitis Media | 1 | 2006 | 144 | 0.060 |
Why?
| | Genetic Heterogeneity | 1 | 2004 | 50 | 0.060 |
Why?
| | Immunophenotyping | 2 | 2020 | 221 | 0.060 |
Why?
| | Pedigree | 2 | 2019 | 455 | 0.060 |
Why?
| | Immunity, Innate | 1 | 2009 | 578 | 0.060 |
Why?
| | Polybrominated Biphenyls | 1 | 2003 | 1 | 0.060 |
Why?
| | Cause of Death | 1 | 2006 | 371 | 0.060 |
Why?
| | Genetics, Population | 1 | 2005 | 188 | 0.060 |
Why?
| | Serotonin Plasma Membrane Transport Proteins | 1 | 2004 | 72 | 0.060 |
Why?
| | Personality Inventory | 1 | 2004 | 143 | 0.060 |
Why?
| | Asthma | 2 | 2007 | 1972 | 0.060 |
Why?
| | Expressed Sequence Tags | 1 | 2003 | 34 | 0.060 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2009 | 771 | 0.060 |
Why?
| | Wnt Proteins | 2 | 2020 | 135 | 0.060 |
Why?
| | Receptors, Antigen, B-Cell | 1 | 2023 | 38 | 0.060 |
Why?
| | High-Throughput Nucleotide Sequencing | 2 | 2019 | 408 | 0.060 |
Why?
| | Membrane Proteins | 1 | 2008 | 839 | 0.060 |
Why?
| | Bile Ducts | 1 | 2003 | 71 | 0.060 |
Why?
| | Breast | 1 | 2003 | 126 | 0.060 |
Why?
| | Hyperplasia | 1 | 2003 | 149 | 0.060 |
Why?
| | Calcium Signaling | 1 | 2004 | 198 | 0.060 |
Why?
| | Sarcoma, Ewing | 1 | 2003 | 69 | 0.060 |
Why?
| | Selection Bias | 1 | 2022 | 31 | 0.060 |
Why?
| | Biguanides | 1 | 2022 | 13 | 0.060 |
Why?
| | Child, Preschool | 3 | 2022 | 8517 | 0.060 |
Why?
| | Bone Morphogenetic Proteins | 1 | 2023 | 134 | 0.060 |
Why?
| | Lymphoma, B-Cell | 1 | 2003 | 100 | 0.060 |
Why?
| | Benchmarking | 1 | 2023 | 144 | 0.060 |
Why?
| | Genes, BRCA2 | 1 | 2002 | 20 | 0.050 |
Why?
| | Epithelial Cells | 2 | 2008 | 881 | 0.050 |
Why?
| | Genes, BRCA1 | 1 | 2002 | 29 | 0.050 |
Why?
| | Biomedical Research | 1 | 2008 | 575 | 0.050 |
Why?
| | Mice, Inbred BALB C | 2 | 2019 | 851 | 0.050 |
Why?
| | Motor Activity | 1 | 2007 | 672 | 0.050 |
Why?
| | Vaccines, Synthetic | 1 | 2022 | 112 | 0.050 |
Why?
| | Adolescent | 5 | 2020 | 17189 | 0.050 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 2023 | 186 | 0.050 |
Why?
| | Entropy | 1 | 2021 | 34 | 0.050 |
Why?
| | Evolution, Molecular | 1 | 2005 | 402 | 0.050 |
Why?
| | Genetic Testing | 1 | 2004 | 371 | 0.050 |
Why?
| | Interleukin-2 | 1 | 2022 | 269 | 0.050 |
Why?
| | Citrullination | 1 | 2020 | 12 | 0.050 |
Why?
| | Health Care Surveys | 2 | 2016 | 526 | 0.050 |
Why?
| | Somatostatin-Secreting Cells | 1 | 2020 | 2 | 0.050 |
Why?
| | Milk, Human | 1 | 2022 | 149 | 0.050 |
Why?
| | Phosphorylation | 2 | 2018 | 1464 | 0.050 |
Why?
| | Immunity, Cellular | 1 | 2022 | 208 | 0.050 |
Why?
| | Human Embryonic Stem Cells | 1 | 2020 | 10 | 0.050 |
Why?
| | Leukocytes, Mononuclear | 1 | 2023 | 461 | 0.050 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 3 | 2009 | 920 | 0.050 |
Why?
| | Somatostatin | 1 | 2020 | 50 | 0.050 |
Why?
| | Receptors, Retinoic Acid | 1 | 2020 | 35 | 0.050 |
Why?
| | Quality of Life | 2 | 2009 | 2286 | 0.050 |
Why?
| | Citalopram | 1 | 2020 | 28 | 0.050 |
Why?
| | Policy | 1 | 2021 | 114 | 0.050 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2022 | 508 | 0.050 |
Why?
| | Support Vector Machine | 1 | 2020 | 36 | 0.050 |
Why?
| | Nutrition Surveys | 1 | 2021 | 218 | 0.050 |
Why?
| | Autoantigens | 1 | 2020 | 169 | 0.050 |
Why?
| | Embryo, Mammalian | 1 | 2020 | 220 | 0.050 |
Why?
| | Binding Sites | 2 | 2017 | 957 | 0.050 |
Why?
| | Virulence | 2 | 2011 | 106 | 0.050 |
Why?
| | Immunoblotting | 3 | 2005 | 281 | 0.050 |
Why?
| | Allosteric Regulation | 1 | 2019 | 71 | 0.050 |
Why?
| | Interferon-gamma | 1 | 2022 | 542 | 0.050 |
Why?
| | Nanog Homeobox Protein | 1 | 2019 | 11 | 0.040 |
Why?
| | Electroencephalography | 1 | 2021 | 442 | 0.040 |
Why?
| | Breast Feeding | 1 | 2022 | 351 | 0.040 |
Why?
| | Polymethyl Methacrylate | 1 | 2019 | 19 | 0.040 |
Why?
| | International Classification of Diseases | 1 | 2020 | 130 | 0.040 |
Why?
| | Disease Susceptibility | 1 | 2020 | 292 | 0.040 |
Why?
| | Epigenesis, Genetic | 2 | 2017 | 489 | 0.040 |
Why?
| | SEER Program | 1 | 2019 | 184 | 0.040 |
Why?
| | Mice, Knockout | 2 | 2020 | 2225 | 0.040 |
Why?
| | Seizures | 1 | 2021 | 333 | 0.040 |
Why?
| | Basic Helix-Loop-Helix Transcription Factors | 1 | 2020 | 211 | 0.040 |
Why?
| | Adjuvants, Immunologic | 1 | 2019 | 142 | 0.040 |
Why?
| | Neuroendocrine Tumors | 1 | 2019 | 59 | 0.040 |
Why?
| | Schizophrenic Psychology | 1 | 2019 | 133 | 0.040 |
Why?
| | Protein Domains | 1 | 2019 | 164 | 0.040 |
Why?
| | Cross-Sectional Studies | 2 | 2021 | 4235 | 0.040 |
Why?
| | Cognition Disorders | 1 | 2003 | 578 | 0.040 |
Why?
| | Mice, SCID | 1 | 2019 | 276 | 0.040 |
Why?
| | Herpesvirus 3, Human | 1 | 2022 | 378 | 0.040 |
Why?
| | Prostatic Hyperplasia | 2 | 2008 | 35 | 0.040 |
Why?
| | Mice, Inbred NOD | 1 | 2019 | 333 | 0.040 |
Why?
| | Inflammation Mediators | 1 | 2020 | 460 | 0.040 |
Why?
| | Protein Stability | 1 | 2018 | 143 | 0.040 |
Why?
| | Melanoma | 1 | 2003 | 578 | 0.040 |
Why?
| | Databases, Protein | 2 | 2007 | 52 | 0.040 |
Why?
| | National Cancer Institute (U.S.) | 1 | 2017 | 40 | 0.040 |
Why?
| | Retrospective Studies | 3 | 2020 | 11800 | 0.040 |
Why?
| | Tissue Scaffolds | 1 | 2019 | 176 | 0.040 |
Why?
| | Michigan | 2 | 2007 | 98 | 0.040 |
Why?
| | Analgesia, Patient-Controlled | 1 | 2016 | 7 | 0.040 |
Why?
| | Sterilization, Tubal | 1 | 2016 | 8 | 0.040 |
Why?
| | Taiwan | 2 | 2007 | 113 | 0.040 |
Why?
| | After-Hours Care | 1 | 2016 | 16 | 0.040 |
Why?
| | Radiotherapy, Intensity-Modulated | 1 | 2017 | 119 | 0.040 |
Why?
| | Live Birth | 1 | 2016 | 46 | 0.040 |
Why?
| | Family | 1 | 2019 | 494 | 0.040 |
Why?
| | Platelet Count | 1 | 2016 | 87 | 0.040 |
Why?
| | Prostate | 2 | 2008 | 159 | 0.040 |
Why?
| | Survivors | 1 | 2019 | 414 | 0.040 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2017 | 287 | 0.040 |
Why?
| | Antibodies, Viral | 1 | 2019 | 467 | 0.040 |
Why?
| | Personnel Staffing and Scheduling | 1 | 2016 | 72 | 0.040 |
Why?
| | Enhancer of Zeste Homolog 2 Protein | 2 | 2007 | 40 | 0.040 |
Why?
| | HEK293 Cells | 1 | 2018 | 560 | 0.040 |
Why?
| | Prostate-Specific Antigen | 2 | 2008 | 168 | 0.040 |
Why?
| | Enzyme Inhibitors | 1 | 2019 | 782 | 0.030 |
Why?
| | Polymerase Chain Reaction | 2 | 2011 | 853 | 0.030 |
Why?
| | Gene Regulatory Networks | 2 | 2007 | 228 | 0.030 |
Why?
| | Particulate Matter | 1 | 2017 | 199 | 0.030 |
Why?
| | Cholesterol, HDL | 1 | 2016 | 172 | 0.030 |
Why?
| | Cell Movement | 1 | 2019 | 733 | 0.030 |
Why?
| | Cognition | 1 | 2003 | 1043 | 0.030 |
Why?
| | Genes, Bacterial | 2 | 2006 | 107 | 0.030 |
Why?
| | Occupational Exposure | 1 | 2018 | 288 | 0.030 |
Why?
| | Models, Molecular | 1 | 2019 | 1104 | 0.030 |
Why?
| | Polycomb Repressive Complex 2 | 2 | 2007 | 53 | 0.030 |
Why?
| | Cardiovascular System | 1 | 2016 | 117 | 0.030 |
Why?
| | Bangladesh | 1 | 2014 | 40 | 0.030 |
Why?
| | Cesarean Section | 1 | 2016 | 162 | 0.030 |
Why?
| | Rats | 1 | 2003 | 5353 | 0.030 |
Why?
| | Epistasis, Genetic | 1 | 2015 | 67 | 0.030 |
Why?
| | GATA1 Transcription Factor | 1 | 2014 | 5 | 0.030 |
Why?
| | Genes, Essential | 1 | 2014 | 23 | 0.030 |
Why?
| | Molecular Sequence Annotation | 1 | 2014 | 74 | 0.030 |
Why?
| | Pilot Projects | 1 | 2018 | 1327 | 0.030 |
Why?
| | CpG Islands | 1 | 2014 | 103 | 0.030 |
Why?
| | Data Collection | 2 | 2007 | 626 | 0.030 |
Why?
| | Neuropsychological Tests | 1 | 2019 | 1124 | 0.030 |
Why?
| | Methylation | 1 | 2014 | 176 | 0.030 |
Why?
| | Organ Specificity | 1 | 2014 | 239 | 0.030 |
Why?
| | North America | 1 | 2014 | 261 | 0.030 |
Why?
| | Pandemics | 1 | 2021 | 1147 | 0.030 |
Why?
| | Receptors, Estrogen | 2 | 2007 | 368 | 0.030 |
Why?
| | Schizosaccharomyces | 1 | 2013 | 40 | 0.030 |
Why?
| | Transcriptome | 1 | 2019 | 711 | 0.030 |
Why?
| | Cell Line | 2 | 2009 | 2311 | 0.030 |
Why?
| | Host-Parasite Interactions | 1 | 2014 | 91 | 0.030 |
Why?
| | Cytokines | 1 | 2020 | 1652 | 0.030 |
Why?
| | RNA Processing, Post-Transcriptional | 1 | 2013 | 74 | 0.030 |
Why?
| | Gene-Environment Interaction | 1 | 2014 | 184 | 0.030 |
Why?
| | Species Specificity | 1 | 2014 | 523 | 0.030 |
Why?
| | Sequence Analysis, DNA | 2 | 2006 | 696 | 0.030 |
Why?
| | Insulin | 1 | 2020 | 1448 | 0.030 |
Why?
| | Databases, Nucleic Acid | 1 | 2012 | 33 | 0.030 |
Why?
| | Carboplatin | 1 | 2012 | 142 | 0.030 |
Why?
| | Cetuximab | 1 | 2012 | 94 | 0.030 |
Why?
| | Hospitalization | 1 | 2020 | 1653 | 0.030 |
Why?
| | Prospective Studies | 3 | 2009 | 5993 | 0.030 |
Why?
| | Colorado | 1 | 2021 | 3934 | 0.030 |
Why?
| | Paclitaxel | 1 | 2012 | 185 | 0.030 |
Why?
| | Mice, Inbred C57BL | 1 | 2020 | 4145 | 0.030 |
Why?
| | Mass Screening | 1 | 2018 | 950 | 0.030 |
Why?
| | In Situ Hybridization | 1 | 2011 | 302 | 0.030 |
Why?
| | Quinazolines | 1 | 2012 | 242 | 0.020 |
Why?
| | Depression | 1 | 2019 | 1158 | 0.020 |
Why?
| | Gene Expression Regulation, Bacterial | 1 | 2011 | 127 | 0.020 |
Why?
| | Cell Death | 1 | 2011 | 276 | 0.020 |
Why?
| | Electrophoresis | 1 | 2009 | 23 | 0.020 |
Why?
| | Pituitary Hormones | 1 | 2009 | 17 | 0.020 |
Why?
| | Infant | 1 | 2022 | 7506 | 0.020 |
Why?
| | Sarcosine Dehydrogenase | 1 | 2009 | 1 | 0.020 |
Why?
| | Glycine N-Methyltransferase | 1 | 2009 | 3 | 0.020 |
Why?
| | Bone Morphogenetic Protein Receptors, Type I | 1 | 2009 | 10 | 0.020 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2017 | 1363 | 0.020 |
Why?
| | Ophthalmoscopy | 1 | 2008 | 30 | 0.020 |
Why?
| | Electroretinography | 1 | 2008 | 41 | 0.020 |
Why?
| | Consanguinity | 1 | 2008 | 46 | 0.020 |
Why?
| | Blood Pressure | 1 | 2016 | 1618 | 0.020 |
Why?
| | Mice, Mutant Strains | 1 | 2009 | 217 | 0.020 |
Why?
| | Interleukin-1beta | 1 | 2011 | 357 | 0.020 |
Why?
| | Gene Library | 1 | 2009 | 108 | 0.020 |
Why?
| | Golgi Apparatus | 1 | 2008 | 68 | 0.020 |
Why?
| | Antineoplastic Agents | 2 | 2012 | 1928 | 0.020 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2013 | 613 | 0.020 |
Why?
| | Keratinocytes | 1 | 2009 | 154 | 0.020 |
Why?
| | Chemical Fractionation | 1 | 2007 | 26 | 0.020 |
Why?
| | Genes | 1 | 2008 | 152 | 0.020 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2012 | 621 | 0.020 |
Why?
| | Chromosomes, Human, 16-18 | 1 | 2007 | 3 | 0.020 |
Why?
| | Chromosomes, Human, 6-12 and X | 1 | 2007 | 4 | 0.020 |
Why?
| | Gene Knockdown Techniques | 1 | 2009 | 292 | 0.020 |
Why?
| | Registries | 1 | 2016 | 1863 | 0.020 |
Why?
| | Feedback | 1 | 2008 | 137 | 0.020 |
Why?
| | Chromosomes, Human, Pair 5 | 1 | 2007 | 24 | 0.020 |
Why?
| | DNA Primers | 1 | 2008 | 460 | 0.020 |
Why?
| | Tomography, Optical Coherence | 1 | 2008 | 128 | 0.020 |
Why?
| | Chromosomes, Human, Pair 3 | 1 | 2007 | 50 | 0.020 |
Why?
| | Polycomb-Group Proteins | 1 | 2007 | 33 | 0.020 |
Why?
| | Chromatography, Liquid | 1 | 2009 | 312 | 0.020 |
Why?
| | Bacteriophage T7 | 1 | 2007 | 3 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2019 | 4522 | 0.020 |
Why?
| | Agaricales | 1 | 2007 | 3 | 0.020 |
Why?
| | Seaweed | 1 | 2007 | 3 | 0.020 |
Why?
| | Food Contamination | 1 | 2007 | 18 | 0.020 |
Why?
| | Neoplasm Transplantation | 1 | 2007 | 217 | 0.020 |
Why?
| | Seafood | 1 | 2007 | 7 | 0.020 |
Why?
| | Data Display | 1 | 2007 | 21 | 0.020 |
Why?
| | Models, Animal | 1 | 2009 | 343 | 0.020 |
Why?
| | Chromosomes, Human | 1 | 2007 | 37 | 0.020 |
Why?
| | Autophagy-Related Proteins | 1 | 2007 | 41 | 0.020 |
Why?
| | Lymphoma | 1 | 2008 | 175 | 0.020 |
Why?
| | Oxidative Stress | 1 | 2013 | 1142 | 0.020 |
Why?
| | Subtraction Technique | 1 | 2007 | 27 | 0.020 |
Why?
| | Oryza | 1 | 2007 | 21 | 0.020 |
Why?
| | Amino Acid Motifs | 1 | 2007 | 149 | 0.020 |
Why?
| | Sequence Analysis, Protein | 1 | 2006 | 28 | 0.020 |
Why?
| | Television | 1 | 2007 | 68 | 0.020 |
Why?
| | Inhibitory Concentration 50 | 1 | 2006 | 76 | 0.020 |
Why?
| | Fishes | 1 | 2007 | 82 | 0.020 |
Why?
| | Water Supply | 1 | 2007 | 68 | 0.020 |
Why?
| | Nucleic Acid Hybridization | 1 | 2006 | 148 | 0.020 |
Why?
| | Ear, Middle | 1 | 2006 | 92 | 0.020 |
Why?
| | Urban Health | 1 | 2006 | 90 | 0.020 |
Why?
| | Antibodies, Monoclonal | 1 | 2012 | 1057 | 0.020 |
Why?
| | Managed Care Programs | 1 | 2007 | 153 | 0.020 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2011 | 1068 | 0.020 |
Why?
| | Lipid Metabolism | 1 | 2009 | 459 | 0.020 |
Why?
| | Drug Design | 1 | 2007 | 151 | 0.020 |
Why?
| | Recombinant Proteins | 1 | 2009 | 1152 | 0.020 |
Why?
| | Fibrocystic Breast Disease | 1 | 2005 | 2 | 0.020 |
Why?
| | E2F Transcription Factors | 1 | 2005 | 50 | 0.020 |
Why?
| | Base Composition | 1 | 2005 | 59 | 0.020 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2007 | 303 | 0.020 |
Why?
| | Oligonucleotide Probes | 1 | 2005 | 43 | 0.020 |
Why?
| | Databases as Topic | 1 | 2005 | 69 | 0.020 |
Why?
| | Housing | 1 | 2006 | 105 | 0.020 |
Why?
| | DNA Probes | 1 | 2005 | 58 | 0.020 |
Why?
| | Skin | 1 | 2009 | 563 | 0.020 |
Why?
| | Bone Morphogenetic Protein Receptors | 1 | 2004 | 4 | 0.020 |
Why?
| | Autopsy | 1 | 2004 | 90 | 0.020 |
Why?
| | Neoplasms, Hormone-Dependent | 1 | 2004 | 40 | 0.020 |
Why?
| | Smad Proteins | 1 | 2004 | 30 | 0.020 |
Why?
| | Receptors, Growth Factor | 1 | 2004 | 50 | 0.020 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2007 | 329 | 0.020 |
Why?
| | Recombination, Genetic | 1 | 2005 | 139 | 0.020 |
Why?
| | Basic-Leucine Zipper Transcription Factors | 1 | 2004 | 29 | 0.020 |
Why?
| | Oligonucleotides | 1 | 2004 | 102 | 0.020 |
Why?
| | Random Allocation | 1 | 2005 | 359 | 0.020 |
Why?
| | Retinal Diseases | 1 | 2004 | 69 | 0.020 |
Why?
| | Receptors, Progesterone | 1 | 2005 | 315 | 0.020 |
Why?
| | Bacterial Proteins | 1 | 2006 | 385 | 0.010 |
Why?
| | Selection, Genetic | 1 | 2005 | 230 | 0.010 |
Why?
| | Overweight | 1 | 2007 | 485 | 0.010 |
Why?
| | Spermidine | 1 | 2002 | 12 | 0.010 |
Why?
| | Spermine | 1 | 2002 | 24 | 0.010 |
Why?
| | Adenosine Monophosphate | 1 | 2002 | 50 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 2006 | 2296 | 0.010 |
Why?
| | Cell Cycle | 1 | 2004 | 509 | 0.010 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2004 | 733 | 0.010 |
Why?
| | Mutation | 1 | 2012 | 2978 | 0.010 |
Why?
| | California | 1 | 2003 | 366 | 0.010 |
Why?
| | Mental Recall | 1 | 2003 | 193 | 0.010 |
Why?
| | Biopsy, Needle | 1 | 2002 | 171 | 0.010 |
Why?
| | Internet | 1 | 2007 | 653 | 0.010 |
Why?
| | Psychiatric Status Rating Scales | 1 | 2003 | 560 | 0.010 |
Why?
| | Comorbidity | 1 | 2006 | 1566 | 0.010 |
Why?
| | Proto-Oncogene Proteins | 1 | 2004 | 593 | 0.010 |
Why?
| | RNA | 1 | 2005 | 649 | 0.010 |
Why?
| | Disease Models, Animal | 1 | 2009 | 3440 | 0.010 |
Why?
| | Stroke | 1 | 2003 | 988 | 0.010 |
Why?
| | Aging | 1 | 2003 | 1559 | 0.010 |
Why?
|
|
Ghosh's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|